Orexigen said it reached a tentative agreement with the FDA to conduct a two-year trial on the heart safety of its pipeline drug Contrave.
Mainly due to safety concerns, the FDA has not approved a new prescription weight loss pill in more than a decade.
Related Articles on Obesity:
Diabetes Group: Bariatric Surgery Fights Type 2 Diabetes in Obese Patients
Half of Americans Expected to be Obese by 2030
Report: Obesity Rates Continued to Rise Last Year
